L. plantarum

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: digestion immunity inflammation

Research Overview

Across the provided abstracts, Lactiplantibacillus plantarum is most extensively studied as a food-associated lactic acid bacterium with probiotic potential and as a functional starter culture in fermented foods. Core research themes include (i) gastrointestinal robustness and host interaction (tolerance to simulated GI conditions, adhesion to intestinal cell lines, and modulation of gut microbiota composition), (ii) antimicrobial activity (including bacteriocin production and broader “probiotic antimicrobials”/postbiotic concepts with antibacterial and antiviral relevance), and (iii) enhancement of food functionality through fermentation-driven biochemical changes. Omics-enabled work (metabolomics, metagenomics, transcriptomics, proteomics/secretomics) is increasingly used to connect strain-specific traits to mechanistic pathways and to characterize fermentation-derived metabolite shifts, as illustrated by metabolomics profiling in quinoa beverages and multi-omics interrogation of host–microbe mechanisms in disease models.

The strongest evidence in these abstracts supports L. plantarum’s safety and technological utility in fermentation (GRAS/QPS status; long history of use), along with consistent in vitro indications of probiotic-relevant properties (acid/bile tolerance, epithelial adhesion, antioxidant and antimicrobial activities). There is also emerging mechanistic evidence for health-related effects in preclinical systems: for example, in mouse models of nonalcoholic steatohepatitis, L. plantarum administration reduced liver inflammation and improved metabolic phenotypes, with multi-omics data implicating microbiome functional shifts and increased circulating L-arginine as a candidate mediator; and in cell-based neuroprotection paradigms, conditioned media/heat-killed preparations and fermented soy milk were associated with reduced oxidative stress markers and modulation of apoptosis- and neurotrophin-related readouts (e.g., Bax/Bcl-2 ratio, caspases, BDNF/TH expression). In foods, combined processing strategies (e.g., protein hydrolysis plus fermentation) show reproducible enhancement of antioxidant activity and increases in specific functional metabolites, supporting a role for L. plantarum in generating bioactive compounds and improving sensory/functional profiles.

Key gaps highlighted by the overall pattern of evidence are the need for more rigorous, strain-resolved and clinically grounded validation of health claims. Many outcomes remain based on in vitro assays, conditioned media/heat-killed preparations, or animal models, which require translation to well-controlled human trials with standardized endpoints, dosing, and product matrices (live vs. heat-killed; fermented foods vs. capsules). Mechanistically, omics studies identify candidate pathways (e.g., antimicrobial compounds, arginine-related metabolism, fermentation-derived metabolites), but causal links, active molecules, and host targets often remain incompletely defined; comparative studies across strains and niches are needed to determine which effects are generalizable versus strain-specific. Additional research is also warranted on durability of microbiome changes, long-term safety in vulnerable populations, and underdeveloped application areas suggested by the abstracts (e.g., skin/cosmetic and autoimmune contexts), where the evidence base appears preliminary or incomplete.

1. What conditions has L. plantarum been studied for?

  • Gut and microbiome-related outcomes (general probiotic effects): Reviews describe L. plantarum strains as having gastrointestinal (GI) resistance/adhesion, antimicrobial activity (including bacteriocins), and the ability to modulate intestinal microbiota composition.

  • Neuroprotection / brain-health–related outcomes (preclinical): One study evaluated “neuroprotective effects against oxidative stress” using cell models and fermented soy milk with L. plantarum KU210152.

  • Nonalcoholic steatohepatitis (NASH) / metabolic liver inflammation (animal model): A mouse study tested L. plantarum in diet-induced NASH models and explored mechanisms via transcriptomics and metagenomics.

  • Helicobacter pylori-associated gastric inflammation (cell + mouse): L. plantarum ZJ316 was studied in infected AGS cells and H. pylori-infected mice for anti-inflammatory effects and microbiota changes.

  • Inflammation/oxidative stress in immune cells (in vitro): L. plantarum T1 cell-free supernatant (CFS) was tested in LPS-stimulated RAW264.7 macrophages for anti-inflammatory and antioxidant effects.

  • Metabolic disorders broadly (review-level): Reviews mention study in metabolic syndrome features such as dyslipidemia/hypercholesterolemia, obesity, and diabetes, and gut disorders such as inflammatory bowel diseases (IBD), but the provided abstracts do not include specific clinical trial results.

  • Food-function outcomes (not diseases): Fermented foods/beverages (soy milk, quinoa beverage, fermented sausage, soybean meal) were studied for antioxidant activity, peptide formation, and nutritional/functional enhancement.

2. Does it work in treating those conditions? Summarize the evidence.

  • Neuroprotection/oxidative stress (cell-based evidence; not clinical): In the KU210152 study, conditioned medium (from HT-29 cells treated with heat-killed LAB) showed neuroprotective signals: reduced ROS, improved cell viability/morphology, decreased Bax/Bcl-2 ratio, inhibited caspase-9 and caspase-3 activity, and increased BDNF and tyrosine hydroxylase (TH) expression in cell models. These findings support mechanistic plausibility but are not direct evidence of treating human neurologic disease.

  • NASH (mouse evidence with mechanistic support): In CD-HFD mice, L. plantarum treatment decreased liver inflammation and improved metabolic phenotypes (e.g., insulin tolerance and hepatic lipid content). RNA-seq showed downregulation of inflammation-related pathways. Metagenomics suggested increased microbial L-arginine biosynthesis genes, and serum arginine was elevated; follow-up experiments indicated L-arginine alone could alleviate liver inflammation in organoids and an MCD diet mouse model. This supports efficacy in animal models and a proposed mechanism, but it does not establish effectiveness in humans with NASH.

  • H. pylori-associated inflammation (cell + mouse evidence): L. plantarum ZJ316 reduced pro-inflammatory cytokine expression in infected AGS cells and inhibited NF-κB signaling (prevented IκBα degradation, reduced p65 phosphorylation and nuclear translocation). In infected mice, oral ZJ316 reduced inflammatory infiltration, lowered TNF-α and PGII, increased IL-10, and shifted gastric microbiota (decreased Prevotella/Desulfovibrio, increased Ligilactobacillus/Akkermansia). This supports anti-inflammatory activity in models; it is not definitive evidence of eradication therapy or clinical benefit in humans.

  • General anti-inflammatory/antioxidant effects (in vitro evidence): L. plantarum T1 CFS reduced NO/iNOS/COX-2 and cytokines (TNF, IL-1β, IL-6) and ROS in macrophages, while increasing antioxidant indicators (SOD, catalase, glutathione). This supports bioactivity in vitro but cannot be assumed to translate to clinical treatment.

  • Gut disorders/metabolic syndrome/psychological disorders (review claims; limited direct evidence in provided abstracts): Reviews state strains “have proven to be valuable” for gut health, metabolic disorders, and brain health, but the abstracts provided here do not include specific human trial outcomes, effect sizes, or dosing.

Overall, the strongest evidence in the provided abstracts is preclinical (cell and mouse). The abstracts support biological plausibility and potential benefit, but they do not establish clinical efficacy for treating human disease.

3. What health benefits does it have?

  • Probiotic functional traits relevant to gut health: Reviews describe food-derived L. plantarum strains with good GI resistance and adhesion, and the ability to regulate intestinal microbiota composition.

  • Antimicrobial activity: Reviews highlight production of bacteriocins and other antimicrobial agents with antibacterial/antiviral activity spectra, potentially supporting intestinal homeostasis and pathogen inhibition.

  • Anti-inflammatory effects (mechanistic evidence): ZJ316 suppressed NF-κB signaling in H. pylori models and reduced inflammatory markers in mice; T1 CFS reduced inflammatory mediators in macrophages.

  • Antioxidant effects (context-dependent): T1 CFS reduced ROS and increased antioxidant indicators in vitro. In food applications, combined protein hydrolysis + L. plantarum fermentation increased antioxidant activity in a quinoa beverage, whereas fermentation alone did not significantly improve antioxidant activity in that study—suggesting benefits may depend on processing and substrate.

  • Potential liver/metabolic benefits (animal model): In NASH mice, L. plantarum improved liver inflammation and metabolic phenotypes, potentially via increased circulating L-arginine.

  • Potential neuroprotective signaling (cell-based): KU210152-related experiments showed reduced oxidative stress markers and increased BDNF/TH expression in cell models and in fermented soy milk context, suggesting possible brain-health relevance, though not proven clinically.

4. Does it have any downsides or side effects?

  • Safety status (general): One review notes L. plantarum is generally regarded as safe (GRAS) with Qualified Presumption of Safety (QPS) status and has a long tradition of use in foods.

  • Evidence gaps in the provided abstracts: The abstracts provided do not report specific adverse events, side-effect rates, or contraindications from human clinical trials.

  • Important limitations/considerations: Many findings here are from in vitro systems (cell-free supernatants, conditioned media) or animal models. Safety and tolerability of a given commercial product depend on the specific strain, dose, formulation, and host factors (e.g., immune status). The abstracts do not address risks in immunocompromised populations, product quality/contamination, or rare probiotic-associated infections.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic findings (i.e., differential benefits/harms based on human genetic variants). They describe mechanistic pathways (e.g., NF-κB signaling modulation; changes in microbial L-arginine biosynthesis and host circulating arginine; changes in BDNF/TH expression in cell models), but they do not link outcomes to specific host genotypes or genetic polymorphisms.

Conclusion based on these abstracts: no evidence provided that L. plantarum is specifically beneficial or harmful for particular genetic variations.

References

  1. A novel approach to Lactiplantibacillus plantarum: From probiotic properties to the omics insights.
    Noemí Echegaray, Birsen Yilmaz, Heena Sharma, Manoj Kumar, Mirian Pateiro, Fatih Ozogul, Jose Manuel Lorenzo (2023) - Microbiological research
  2. Probiotic Lactiplantibacillus plantarum KU210152 and its fermented soy milk attenuates oxidative stress in neuroblastoma cells.
    Hyun-Ji Bock, Hye-Won Lee, Na-Kyoung Lee, Hyun-Dong Paik (2024) - Food research international (Ottawa, Ont.)
  3. The combined effect of protein hydrolysis and Lactobacillus plantarum fermentation on antioxidant activity and metabolomic profiles of quinoa beverage.
    Fan-Bing Meng, Li Zhou, Jia-Jia Li, Yun-Cheng Li, Meng Wang, Long-Hua Zou, Da-Yu Liu, Wei-Jun Chen (2022) - Food research international (Ottawa, Ont.)
  4. Bioprospecting Antimicrobials fromLactiplantibacillus plantarum: Key Factors Underlying Its Probiotic Action
    Maria Teresa Rocchetti, Pasquale Russo, Vittorio Capozzi, Djamel Drider, Giuseppe Spano (2021)
  5. New perspectives of Lactobacillus plantarum as a probiotic: The gut-heart-brain axis.
    Yen-Wenn Liu, Min-Tze Liong, Ying-Chieh Tsai (2018) - Journal of microbiology (Seoul, Korea)
  6. Lactobacillus plantarum ameliorates NASH-related inflammation by upregulating L-arginine production.
    Dong Yun Kim, Jun Yong Park, Heon Yung Gee (2023) - Experimental & molecular medicine
  7. Regulatory effects of
    Wan-Hua Tsai, Chia-Hsuan Chou, Ying-Ju Chiang, Ching-Gong Lin, Che-Hsin Lee (2021) - International journal of medical sciences
  8. Akkermansia muciniphila and Lactobacillus plantarum ameliorate systemic lupus erythematosus by possibly regulating immune response and remodeling gut microbiota.
    Mengchen Guo, Mei Lu, Kun Chen, Rui Xu, Yumin Xia, Xingyin Liu, Zhi Liu, Qisha Liu (2023) - mSphere
  9. Effect of Probiotic
    Yan Zeng, Ahmed Fadaak, Nora Alomeir, Yan Wu, Tong Tong Wu, Shuang Qing, Jin Xiao (2023) - International journal of molecular sciences
  10. Effect of
    Naiyong Xiao, Qiang Zhang, Huiya Xu, Changliang Zheng, Yantao Yin, Shucheng Liu, Wenzheng Shi (2024) - Food chemistry: X
  11. Effect of Lactobacillus plantarum on antioxidant activity in fermented sausage.
    Xiaoxu Luan, Meiqin Feng, Jian Sun (2021) - Food research international (Ottawa, Ont.)
  12. Possible modulating functions of probiotic
    Nishant Gupta, N S Abd El-Gawaad, Suhad Ali Osman Abdallah, M Al-Dossari (2023) - Frontiers in cellular and infection microbiology
  13. Anti-inflammatory effect ofLactiplantibacillus plantarumT1 cell-free supernatants through suppression of oxidative stress and NF-κB- and MAPK-signaling pathways
    Rui Hao, Qianqian Liu, Lu Wang, Wenwen Jian, Yu Cheng (2023)
  14. Lactic acid bacteria target NF-κB signaling to alleviate gastric inflammation
    Shiying Wu, Yuenuo Luo, Fangtong Wei, Yanan Li, Jiayi Fan (2025)
  15. Effect of Bacillus subtilis and Lactobacillus plantarum on solid-state fermentation of soybean meal.
    Qianqian Chen, Bo Liu, Guohong Liu, Huai Shi, Jieping Wang (2023) - Journal of the science of food and agriculture
  16. Lactobacillus plantarum WCFS1 and its host interaction: a dozen years after the genome.
    Maurits van den Nieuwboer, Saskia van Hemert, Eric Claassen, Willem M de Vos (2016) - Microbial biotechnology
  17. Lactiplantibacillus plantarum 299v (LP299V®): three decades of research.
    E Arvidsson Nordström, C Teixeira, C Montelius, B Jeppsson, N Larsson (2021) - Beneficial microbes
  18. Bacterial Dynamics of Wheat Silage.
    Jitendra Keshri, Yaira Chen, Riky Pinto, Yulia Kroupitski, Zwi G Weinberg, Shlomo Sela Saldinger (2019) - Frontiers in microbiology
  19. Lactobacillus plantarum L168 improves hyperoxia-induced pulmonary inflammation and hypoalveolarization in a rat model of bronchopulmonary dysplasia.
    Xian Shen, Zhaocong Yang, Qiang Wang, Xu Chen, Qihui Zhu, Zhi Liu, Nishant Patel, Xingyin Liu, Xuming Mo (2024) - NPJ biofilms and microbiomes
  20. Mixed
    Jun Chen, Liyu Mou, Lei Wang, Guofang Wu, Ximei Dai, Qiufang Chen, Jianbo Zhang, Xuan Luo, Fafang Xu, Miao Zhang, Yaoke Duan, Huili Pang, Yanping Wang, Yimin Cai, Zhongfang Tan (2024) - Frontiers in microbiology


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!